Radelumin - ABX advanced biochemical compounds GmbH
Alternative Names: [18F]-PSMA-1007; F-18-PSMA-1007; Fluorine-18 PSMA 1007 - ABX advanced biochemical compounds GmbH; PB-01 - Primo BiotechnologyLatest Information Update: 31 Jul 2025
At a glance
- Originator German Cancer Research Center
- Developer Advanced Biochemical Compounds (ABX GmbH); Centre for Probe Development and Commercialization
- Class Amides; Imaging agents; Naphthalenes; Pyridines; Radioisotopes; Radiopharmaceutical diagnostics; Urea compounds
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Prostate cancer
- Phase II Glioblastoma
Most Recent Events
- 05 May 2025 ABX advanced biochemical compounds completes a phase III trial in Prostate cancer (Diagnosis) in Netherlands, USA, Switzerland (IV) (NCT04742361) (EUdraCT2020-004235-24)
- 19 Mar 2025 Primo Biotechnology and ABX advanced biochemical compounds GmbH enters into a strategic partnership for PB01
- 19 Mar 2025 Primo Biotechnology plans to launch PB 01 in Taiwan